- Current report filing (8-K)
January 12 2010 - 8:12AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
Current
Report Pursuant to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
January
12, 2010
Date of
Report (Date of earliest event reported)
OSI PHARMACEUTICALS,
INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
0-15190
|
13-3159796
|
(State
or other jurisdiction of
incorporation)
|
(Commission
File
Number)
|
(I.R.S.
Employer
Identification
No.)
|
41
Pinelawn Road
Melville,
NY 11747
(Address
of principal executive offices)
(631)
962-2000
(Registrant's
telephone number, including area code)
N/A
(Former
name or former address,
if
changed since last report.)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
¨
|
Written
communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a
12)
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item 2.02.
Results of Operations and Financial
Condition
On January 12, 2010,
OSI Pharmaceuticals, Inc.
issued a press release
announcing that it will present today,
at the 28
th
Annual JP Morgan Healthcare Conference
in San Francisco, California, worldwide net sales of Tarceva® (erlotinib) for
the three and twelve months ending December 31, 2009.
A copy of this release is attached
hereto as Exhibit 99.1 and is incorporated herein by
reference.
The
information in this Item 2.02 (including Exhibit 99.1) is being “furnished” and
shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to
the liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, whether made before or after the date of this report, except as
shall be expressly set forth by specific reference in such filing.
Item 9.01.
Financial Statements and Exhibits.
Exhibit
No.
|
Description
|
|
|
99.1
|
Press
Release dated January 12, 2010.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Date: January
12, 2010
|
OSI
PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Barbara A. Wood
|
|
|
|
Barbara
A. Wood
|
|
|
|
Senior
Vice President, General Counsel and
Secretary
|
EXHIBIT
INDEX
Exhibit
No.
|
Description
|
|
|
99.1
|
Press
Release dated January 12, 2010.
|
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jul 2023 to Jul 2024